30
Participants
Start Date
January 8, 2019
Primary Completion Date
June 1, 2020
Study Completion Date
July 8, 2020
M6620
M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
Massachusetts General Hospital Cancer Center, Boston
Beth Israel Deaconess Medical Center, Boston
Boston Children Hospital, Boston
Dana Farber Cancer Institute, Boston
Collaborators (1)
EMD Serono
INDUSTRY
Massachusetts General Hospital
OTHER